These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24690227)

  • 21. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vagomimetic effects of fingolimod: physiology and clinical implications.
    Vanoli E; Pentimalli F; Botto G
    CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
    Popova NF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166
    [No Abstract]   [Full Text] [Related]  

  • 24. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
    Castillo-Trivino T; Lopetegui I; Alarcón-Duque JA; López de Munain A; Olascoaga J
    J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):931-2. PubMed ID: 25835036
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
    Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
    Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed cardiac dysrhythmias after fingolimod administration.
    Rosini JM; Rajasimhan S; Fellows SE; Nomura JT
    Am J Emerg Med; 2015 Jul; 33(7):987.e1-3. PubMed ID: 25669873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
    J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
    Al-Hashel J; Ahmed SF; Behbehani R; Alroughani R
    CNS Drugs; 2014 Sep; 28(9):817-24. PubMed ID: 25011422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early tolerability and safety of fingolimod in clinical practice.
    Ontaneda D; Hara-Cleaver C; Rudick RA; Cohen JA; Bermel RA
    J Neurol Sci; 2012 Dec; 323(1-2):167-72. PubMed ID: 23040960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of fingolimod in clinical practice.
    Thomas K; Ziemssen T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S60-4. PubMed ID: 24321158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.
    Thomas K; Schrötter H; Halank M; Ziemssen T
    BMC Neurol; 2014 Jun; 14():126. PubMed ID: 24906818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
    Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X
    Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
    Klatt J; Hartung HP; Hohlfeld R
    Nervenarzt; 2007 Oct; 78(10):1200-8. PubMed ID: 17668161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].
    Winkelmann A; Löbermann M; Reisinger EC; Zettl UK
    Nervenarzt; 2012 Feb; 83(2):236-42. PubMed ID: 21845450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged and symptomatic bradycardia following a single dose of fingolimod.
    Faber H; Fischer HJ; Weber F
    Mult Scler; 2013 Jan; 19(1):126-8. PubMed ID: 22729989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
    Fazekas F; Berger T; Fabjan TH; Ledinek AH; Jakab G; Komoly S; Kraus J; Kurča E; Kyriakides T; Lisý L; Milanov I; Panayiotou P; Jazbec SS; Taláb R; Traykov L; Turčáni P; Vass K; Vella N; Havrdová E
    Wien Med Wochenschr; 2012 Aug; 162(15-16):354-66. PubMed ID: 22895849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.